期刊文献+

抗肿瘤坏死因子疗法在炎症性肠病中的应用 被引量:1

Application of Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
下载PDF
导出
摘要 目前,抗肿瘤坏死因子疗法在炎症性肠病的治疗中发挥着重要的作用。在炎症性肠病中使用抗肿瘤坏死因子抗体可能是至关重要的,以实现最终目的即肠道黏膜愈合。在疾病的早期阶段,特别是在克罗恩病患者中,建议使用抗肿瘤坏死因子抗体。但由于其成本、副作用、药物浓度监测等问题,使抗肿瘤坏死因子抗体备受争议。本文就最新相关数据来探讨抗肿瘤坏死因子抗体在炎症性肠病中的应用。 At present,the anti-tumor necrosis factor therapy plays an important role in the treatment of inflammatory bowel disease.Using of anti-tumor necrosis factor antibody in inflammatory bowel disease in order to achieve the ultimate objective of intestinal mucosal healing may be crucial. In the early stages of the disease,especially in Crohn's disease,it is recommended to use anti-tumor necrosis factor antibody. However,due to its cost,side effects,drug concentration monitoring and other issues,using of anti-tumor necrosis factor antibody is controversial. In this paper,the application of anti-tumor necrosis factor antibody in inflammatory bowel disease is explored with the latest data.
出处 《沈阳医学院学报》 2016年第2期102-105,共4页 Journal of Shenyang Medical College
关键词 抗肿瘤坏死因子疗法 黏膜愈合 溃疡性结肠炎 克罗恩病 anti-tumor necrosis factor therapy mucosal healing ulcerative colitis Crohn's disease
  • 相关文献

参考文献5

二级参考文献108

  • 1Pineton de Chambrun G, Peyrin-Biroulet L, Iémann M, et al. Clinical implications of mueosal healing for the management of IBD. Nat tlev Gastroenterol Hepatol, 2010, 7 (1): 15-29.
  • 2Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d' Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut, 1989, 30 (7): 983-989.
  • 3Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic aetivity score for Crohn's disease: the SES- CD. Gastrointest Endose, 2004, 60 (4): 505-512.
  • 4Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology, 1990, 99 (4): 956-963.
  • 5Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn' s disease. Gastroenterology, 2004, 126 (2): 402-413.
  • 6Colombel JF, Sandbom WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med, 2010, 362 (15): 1383-1395.
  • 7Bjǒrkesten CG, Nieminen U, Turunen U, et al.Endoscopic monitoring of infliximab therapy in Crohn's disease. Inflamm Bowel Dis, 2010, Sep 21. [Epub ahead of print].
  • 8Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis, 2009, 15 (3): 375-382.
  • 9Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol, 2010, 7 (2): 79-85.
  • 10Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology, 2010, 138 (2): 463-468.

共引文献1054

同被引文献8

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部